122 related articles for article (PubMed ID: 19073252)
1. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men.
Lundahl A; Hedeland M; Bondesson U; Knutson L; Lennernäs H
Eur J Pharm Sci; 2009 Mar; 36(4-5):433-43. PubMed ID: 19073252
[TBL] [Abstract][Full Text] [Related]
2. Undeclared exposure to St. John's Wort in hospitalized patients.
Martin-Facklam M; Rieger K; Riedel KD; Burhenne J; Walter-Sack I; Haefeli WE
Br J Clin Pharmacol; 2004 Oct; 58(4):437-41. PubMed ID: 15373938
[TBL] [Abstract][Full Text] [Related]
3. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
Mai I; Bauer S; Perloff ES; Johne A; Uehleke B; Frank B; Budde K; Roots I
Clin Pharmacol Ther; 2004 Oct; 76(4):330-40. PubMed ID: 15470332
[TBL] [Abstract][Full Text] [Related]
4. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry.
Riedel KD; Rieger K; Martin-Facklam M; Mikus G; Haefeli WE; Burhenne J
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):27-33. PubMed ID: 15556512
[TBL] [Abstract][Full Text] [Related]
6. St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants.
Klier CM; Schmid-Siegel B; Schäfer MR; Lenz G; Saria A; Lee A; Zernig G
J Clin Psychiatry; 2006 Feb; 67(2):305-9. PubMed ID: 16566628
[TBL] [Abstract][Full Text] [Related]
7. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
8. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
9. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers.
Morimoto T; Kotegawa T; Tsutsumi K; Ohtani Y; Imai H; Nakano S
J Clin Pharmacol; 2004 Jan; 44(1):95-101. PubMed ID: 14681347
[TBL] [Abstract][Full Text] [Related]
10. Effect of eluent pH on the HPLC-UV analysis of hyperforin from St. John's Wort (Hypericum perforatum L.).
Fourneron JD; Naït-Si Y
Phytochem Anal; 2006; 17(2):71-7. PubMed ID: 16634282
[TBL] [Abstract][Full Text] [Related]
11. Instability of St. John's wort (Hypericum perforatum L.) and degradation of hyperforin in aqueous solutions and functional beverage.
Ang CY; Hu L; Heinze TM; Cui Y; Freeman JP; Kozak K; Luo W; Liu FF; Mattia A; DiNovi M
J Agric Food Chem; 2004 Oct; 52(20):6156-64. PubMed ID: 15453681
[TBL] [Abstract][Full Text] [Related]
12. Measurement of hyperforin a constituent of St. John's wort in plasma by high-performance liquid chromatography.
Chi JD; Franklin M
J Chromatogr B Biomed Sci Appl; 1999 Dec; 735(2):285-8. PubMed ID: 10670742
[TBL] [Abstract][Full Text] [Related]
13. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(1):15-22. PubMed ID: 15727160
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes.
Hokkanen J; Tolonen A; Mattila S; Turpeinen M
Eur J Pharm Sci; 2011 Feb; 42(3):273-84. PubMed ID: 21168483
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.
Hu ZP; Yang XX; Chen X; Cao J; Chan E; Duan W; Huang M; Yu XQ; Wen JY; Zhou SF
Curr Drug Metab; 2007 Feb; 8(2):157-71. PubMed ID: 17305494
[TBL] [Abstract][Full Text] [Related]
17. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers.
Lei HP; Yu XY; Xie HT; Li HH; Fan L; Dai LL; Chen Y; Zhou HH
Xenobiotica; 2010 Apr; 40(4):275-81. PubMed ID: 20102294
[TBL] [Abstract][Full Text] [Related]
18. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility.
Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA
J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886
[TBL] [Abstract][Full Text] [Related]
19. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse.
Cantoni L; Rozio M; Mangolini A; Hauri L; Caccia S
Toxicol Sci; 2003 Sep; 75(1):25-30. PubMed ID: 12857935
[TBL] [Abstract][Full Text] [Related]
20. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers.
Biber A; Fischer H; Römer A; Chatterjee SS
Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():36-43. PubMed ID: 9684946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
